Literature DB >> 2428328

Cerebrospinal fluid amine metabolites. Relationships with behavioral measurements in depressed, manic, and healthy control subjects.

D E Redmond, M M Katz, J W Maas, A Swann, R Casper, J M Davis.   

Abstract

We studied 99 hospitalized depressed, 14 manic, and 61 healthy control subjects and evaluated relationships during a drug-free baseline period between behavioral measures (postulated to be associated with brain norepinephrine, dopamine, and serotonin function) and metabolites of these neurotransmitters sampled from lumbar cerebrospinal fluid (CSF): 3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid, and 5-hydroxyindoleacetic acid. Depressed subjects with increased anxiety, agitation, somatization, and sleep disturbance were found to have significantly elevated concentrations of CSF MHPG; this relationship was not found in the healthy controls. A correlation between CSF MHPG level and an anxiety/agitation dimension measured in all subjects was statistically significant but explained a modest portion of the total variance. No consistent relationships were found between CSF MHPG and depression/retardation, hostility/interpersonal sensitivity, and global severity, nor did any of these measures correlate significantly with the levels of the other monoamine metabolites, although some trends were found. Other factors did not account for the relationships between CSF MHPG and some behavioral measures, including diagnostic subgroup, motor movement, age, sex, and premenopausal or postmenopausal status in women. Suggested relationships among drug treatment modality, eventual treatment outcome, behavioral and mood state at baseline, and these metabolite levels will require further analyses.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2428328     DOI: 10.1001/archpsyc.1986.01800100028005

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  5 in total

1.  Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia.

Authors:  G L Corona; M L Cucchi; P Frattini; G Santagostino; S Schinelli; A Romani; A Pola; F Zerbi; F Savoldi
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1989

2.  The project for objective measures using computational psychiatry technology (PROMPT): Rationale, design, and methodology.

Authors:  Taishiro Kishimoto; Akihiro Takamiya; Kuo-Ching Liang; Kei Funaki; Takanori Fujita; Momoko Kitazawa; Michitaka Yoshimura; Yuki Tazawa; Toshiro Horigome; Yoko Eguchi; Toshiaki Kikuchi; Masayuki Tomita; Shogyoku Bun; Junichi Murakami; Brian Sumali; Tifani Warnita; Aiko Kishi; Mizuki Yotsui; Hiroyoshi Toyoshiba; Yasue Mitsukura; Koichi Shinoda; Yasubumi Sakakibara; Masaru Mimura
Journal:  Contemp Clin Trials Commun       Date:  2020-08-18

3.  Urapidil permeates the intact blood-brain barrier.

Authors:  G Castor; U Schmidt
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

4.  Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls.

Authors:  Erik Pålsson; Carl Sellgren; Eleonore Rydén; Ruth Kizza; Aurimantas Pelanis; Henrik Zetterberg; Kaj Blennow; Mikael Landén
Journal:  J Neural Transm (Vienna)       Date:  2017-06-27       Impact factor: 3.575

Review 5.  Integrated neurobiology of bipolar disorder.

Authors:  Vladimir Maletic; Charles Raison
Journal:  Front Psychiatry       Date:  2014-08-25       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.